Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
George M. Warimwe, Joseph Gesharisha, B. Veronica Carr, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 107

Showing 26-50 of 107 citing articles:

A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep
Bonto Faburay, William C. Wilson, Natasha N. Gaudreault, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 52
Vaccine platforms for the prevention of Lassa fever
Jyothi N. Purushotham, Teresa Lambe, Sarah C. Gilbert
Immunology Letters (2019) Vol. 215, pp. 1-11
Open Access | Times Cited: 49
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge
Robert J. Fischer, Jyothi N. Purushotham, Neeltje van Doremalen, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 40
Adenovirus vectored veterinary vaccines
F.K. Dar, Shermila Kulanayake, Sambulo Ndlovu, et al.
Elsevier eBooks (2025), pp. 657-685
Closed Access
Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate
Tetsuro Ikegami
Expert Review of Vaccines (2017) Vol. 16, Iss. 6, pp. 601-611
Open Access | Times Cited: 44
Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
Alessandra Vitelli, Antonella Folgori, Elisa Scarselli, et al.
Expert Review of Vaccines (2017) Vol. 16, Iss. 12, pp. 1241-1252
Closed Access | Times Cited: 43
Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
Anna Stedman, Daniel Wright, Paul J. Wichgers Schreur, et al.
npj Vaccines (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 41
Designing of a multi-epitopes-based peptide vaccine against rift valley fever virus and its validation through integrated computational approaches
Israr Fatima, Sajjad Ahmad, Sumra Wajid Abbasi, et al.
Computers in Biology and Medicine (2021) Vol. 141, pp. 105151-105151
Closed Access | Times Cited: 27
Experimental Infection of Calves by Two Genetically-Distinct Strains of Rift Valley Fever Virus
William C. Wilson, A. Sally Davis, Natasha N. Gaudreault, et al.
Viruses (2016) Vol. 8, Iss. 5, pp. 145-145
Open Access | Times Cited: 36
Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle
Pawan Dulal, Daniel Wright, Rebecca Ashfield, et al.
Vaccine (2016) Vol. 34, Iss. 20, pp. 2296-2298
Open Access | Times Cited: 32
Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle
Paul J. Wichgers Schreur, Nadia Oreshkova, Lucien van Keulen, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 28
Using cross-species vaccination approaches to counter emerging infectious diseases
George M. Warimwe, Michael J. Francis, Thomas A. Bowden, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 12, pp. 815-822
Open Access | Times Cited: 25
Sustaining Livestock Production Under the Changing Climate: Africa Scenario for Nigeria Resilience and Adaptation Actions
Akeem Babatunde Sikiru, Silpa Mullakkalparambil Velayyudhan, M. R. Reshma Nair, et al.
Springer climate (2023), pp. 233-259
Closed Access | Times Cited: 9
A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
Teresa Lambe, Georgina Bowyer, Katie Ewer
Philosophical Transactions of the Royal Society B Biological Sciences (2017) Vol. 372, Iss. 1721, pp. 20160295-20160295
Open Access | Times Cited: 31
Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
Sarah C. Gilbert, George M. Warimwe
Vaccine (2017) Vol. 35, Iss. 35, pp. 4461-4464
Open Access | Times Cited: 31
The first positive serological study on rift valley fever in ruminants of Iran
Shahin Fakour, Salahedin Naserabadi, Elham Ahmadi
Journal of Vector Borne Diseases (2017) Vol. 54, Iss. 4, pp. 348-348
Open Access | Times Cited: 31
Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study
Moataz Alhaj
Journal of Immunology Research (2016) Vol. 2016, pp. 1-7
Open Access | Times Cited: 29
Participatory survey of Rift Valley fever in nomadic pastoral communities of North-central Nigeria: The associated risk pathways and factors
Nma Bida Alhaji, Olutayo Olajide Babalobi, Yiltawe Wungak, et al.
PLoS neglected tropical diseases (2018) Vol. 12, Iss. 10, pp. e0006858-e0006858
Open Access | Times Cited: 28
Vaccine Development for Nipah Virus Infection in Pigs
Rebecca McLean, Simon P. Graham
Frontiers in Veterinary Science (2019) Vol. 6
Open Access | Times Cited: 28
Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
Rasoul Mirzaei, Rokhsareh Mohammadzadeh, Farzad Mahdavi, et al.
International Immunopharmacology (2020) Vol. 88, pp. 106928-106928
Open Access | Times Cited: 27
UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments
Rob Noad, Karl Simpson, Anthony R. Fooks, et al.
Vaccine (2019) Vol. 37, Iss. 43, pp. 6241-6247
Open Access | Times Cited: 26
Immune correlates of protection following Rift Valley fever virus vaccination
Joshua D. Doyle, Dominique J. Barbeau, Haley N. Cartwright, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 15
Development of Middle East Respiratory Syndrome Coronavirus vaccines – advances and challenges
Heeyoun Cho, Jean‐Louis Excler, Jérôme H. Kim, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 14, Iss. 2, pp. 304-313
Open Access | Times Cited: 27
Association between Rift Valley fever virus seroprevalences in livestock and humans and their respective intra-cluster correlation coefficients, Tana River County, Kenya
Bernard Bett, Johanna F. Lindahl, Rosemary Sang, et al.
Epidemiology and Infection (2018) Vol. 147
Open Access | Times Cited: 27
Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination
Gema Lorenzo, Elena López-Gil, Javier Ortego, et al.
Veterinary Research (2018) Vol. 49, Iss. 1
Open Access | Times Cited: 26

Scroll to top